ArticleJournal of translational medicine2026
Deciphering elevated risk of life-threatening hemorrhage and early death in acute myeloid leukemia with APL-like phenotype: independent role of endothelial injury and implications of EASIX-based risk stratification in a multicenter study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly hemorrhagic mortality remains the major cause of elevated early death (ED) incidence in acute promyelocytic leukemia (APL)-like subgroup of acute myeloid leukemia (AML). The underlying mechanisms remain unknown and risk-adapted management strategies are not well established. We aimed to investigate the significance of endothelial injury in major bleeding event (MBE) and ED of APL-like AML (APLL) using endothelial activation and stress index (EASIX), and to develop an EASIX-based risk stratification with translational implications on APLL in venetoclax (VEN) era.
methodsThis multicenter study investigated newly diagnosed AML patients from three Chinese institutions between January 2017 and September 2025. Propensity score matching (PSM) and prospective thrombomodulin (TM) measurements were applied to validate EASIX utility in APLL. The APLL cohort was divided into development and validation cohorts based on diagnostic institutions to establish an MBE risk stratification using logistic regression.
resultsOf 344 APLL, 212 APL, and 1596 'Other AML' in the analysis, log2-EASIX of APLL was comparable to APL but significantly higher than 'Other AML' (3.777 vs. 2.692, P < 0.001), which was sustained after PSM (4.022 vs. 2.904, P < 0.001). Significant correlation was further validated between log2-EASIX and TM (r = 0.80, P < 0.001). Within APLL, high log2-EASIX (OR: 5.611, 95% CI: 2.212-14.233, P < 0.001), overt DIC at diagnosis (OR: 2.929, 95% CI: 1.127-7.616, P = 0.027) and CD56 + blasts (OR: 3.697, 95% CI: 1.691-8.082, P = 0.001) emerged as independent MBE risk factors, setting foundation for a novel risk stratification. High-risk APLL exhibited significantly higher cumulative ED incidence in both development and validation cohorts, particularly when treated with standard VEN combining hypomethylating agent (HMA) regimen (P < 0.05 in both cohorts). However, modified VEN-HMA regimen with reduced VEN initiation dose specifically improved early outcomes of high-risk APLL (P = 0.036) in an independent, real-world implementation cohort.
conclusionsAPLL is characterized by significant endothelial damage, which is quantifiable by EASIX to independently contribute to the elevated MBE risk. The EASIX-based stratification can be utilized to rapidly identify high-risk APLL, who may benefit from an optimized VEN-HMA induction strategy to reduce ED risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.